Change of NLRP3 Inflammasome Expression Level, Symptoms, and Functional Status in HFpEF Patients Treated With ARNI
NCT ID: NCT04269057
Last Updated: 2020-02-17
Study Results
The study team has not published outcome measurements, participant flow, or safety data for this trial yet. Check back later for updates.
Basic Information
Get a concise snapshot of the trial, including recruitment status, study phase, enrollment targets, and key timeline milestones.
UNKNOWN
90 participants
OBSERVATIONAL
2019-10-01
2020-10-01
Brief Summary
Review the sponsor-provided synopsis that highlights what the study is about and why it is being conducted.
Related Clinical Trials
Explore similar clinical trials based on study characteristics and research focus.
The Relationship Between Heart Function and Metabolism in HFpEF Patients
NCT05053256
The Correlation Between Serum PRMT5 Level and Cardiac Ultrasound Indicators in Patients With Heart Failure
NCT07050706
Inflammation, Epigenetics in CHF Patients With AF
NCT07152301
Study of the Clinical Scoring System and Cytokines for Prediction of Inflammatory Response in Major Surgery
NCT01353157
LYmphangiogenesis FacTors in Heart Failure States
NCT03141567
Detailed Description
Dive into the extended narrative that explains the scientific background, objectives, and procedures in greater depth.
Conditions
See the medical conditions and disease areas that this research is targeting or investigating.
Study Design
Understand how the trial is structured, including allocation methods, masking strategies, primary purpose, and other design elements.
COHORT
RETROSPECTIVE
Study Groups
Review each arm or cohort in the study, along with the interventions and objectives associated with them.
HFpEF
heart failure patients with preserved ejection fraction who using ARNI
No interventions assigned to this group
HFrEF
heart failure patients with reduced ejection fraction who using ARNI
No interventions assigned to this group
Eligibility Criteria
Check the participation requirements, including inclusion and exclusion rules, age limits, and whether healthy volunteers are accepted.
Inclusion Criteria
* with the symptoms and/or signs of heart failure；
* BNP≥35 pg/mL and/or NTproBNP≥125 pg/mL；
* at least one additional criterion: relevant structural heart disease(LVH and/or LAE) or diastolic dysfunction.
Exclusion Criteria
* severe infection;
* ACS;
* pregnancy;
* eGFR \<30 mL/min/1.73 m2, etc.
ALL
No
Sponsors
Meet the organizations funding or collaborating on the study and learn about their roles.
Chongqing Medical University
OTHER
Responsible Party
Identify the individual or organization who holds primary responsibility for the study information submitted to regulators.
Dongying Zhang
Associate Professor
Principal Investigators
Learn about the lead researchers overseeing the trial and their institutional affiliations.
Dongying Zhang, doctor
Role: STUDY_DIRECTOR
First Affiliated Hospital of Chongqing Medical University
Locations
Explore where the study is taking place and check the recruitment status at each participating site.
The First Affiliated Hospital of Chongqing Medical University
Chongqing, , China
Countries
Review the countries where the study has at least one active or historical site.
Central Contacts
Reach out to these primary contacts for questions about participation or study logistics.
Facility Contacts
Find local site contact details for specific facilities participating in the trial.
Other Identifiers
Review additional registry numbers or institutional identifiers associated with this trial.
2019-10
Identifier Type: -
Identifier Source: org_study_id
More Related Trials
Additional clinical trials that may be relevant based on similarity analysis.